GlassScriptPhysician profile
Mark M Tungesvik
NPI 1497723472
$14,421.88
in general payments reported to CMS, 2019-2025
66 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,950 · 2020: $773 · 2021: $1,411 · 2022: $2,194 · 2023: $1,867 · 2024: $2,280 · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,302 · Education: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.64 |
| Education | $792.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,250.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,013.61 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $980.10 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $894.65 | 2019-2025 | |
| Celgene Corporation | $829.46 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $800.47 | 2019-2025 | Tukysa |
| Incyte Corporation | $723.45 | 2019-2025 | Jakafi, Niktimvo, Pemazyre |
| Genentech USA, INC. | $708.76 | 2019-2025 | Tecentriq, Itovebi, Polivy |
| Janssen Biotech, INC. | $690.76 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $647.13 | 2021-2025 | Venclexta, Creon |
| Astrazeneca Pharmaceuticals LP | $640.58 | 2019-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $594.20 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Gilead Sciences, INC. | $449.32 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $386.54 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $322.14 | 2019-2025 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tungesvik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.